Who are insulin human (HR1799)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intraoperative continuous insulin infusion, Insulin human/Novolin® 30R.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/insulin-human-hr1799.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

insulin human (HR1799) — Competitive Intelligence Brief

insulin human (HR1799) (insulin human (HR1799)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin (human recombinant). Area: Diabetes.

marketed Insulin (human recombinant) Insulin receptor (INSR) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

insulin human (HR1799) (insulin human (HR1799)) — Sanofi. Insulin human (HR1799) is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and regulate blood glucose levels.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
insulin human (HR1799) TARGET	insulin human (HR1799)	Sanofi	marketed	Insulin (human recombinant)	Insulin receptor (INSR)
Intraoperative continuous insulin infusion	Intraoperative continuous insulin infusion	Rabin Medical Center	marketed	Insulin (human recombinant)	Insulin receptor
Insulin human/Novolin® 30R	Insulin human/Novolin® 30R	Sanofi	phase 3	Insulin (human recombinant)	Insulin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin (human recombinant) class)

Sanofi · 2 drugs in this class
Rabin Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). insulin human (HR1799) — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-human-hr1799. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab